GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (BSP:G1LP34) » Definitions » Other Stockholders Equity

Galapagos NV (BSP:G1LP34) Other Stockholders Equity : R$0 Mil (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Galapagos NV Other Stockholders Equity?

Galapagos NV's Other Stockholders Equity for the quarter that ended in Mar. 2024 was R$0 Mil.

Galapagos NV's quarterly Other Stockholders Equity declined from Sep. 2023 (R$0 Mil) to Dec. 2023 (R$-0 Mil) but then increased from Dec. 2023 (R$-0 Mil) to Mar. 2024 (R$0 Mil).

Galapagos NV's annual Other Stockholders Equity increased from Dec. 2021 (R$-0 Mil) to Dec. 2022 (R$-0 Mil) but then declined from Dec. 2022 (R$-0 Mil) to Dec. 2023 (R$-0 Mil).


Galapagos NV Other Stockholders Equity Historical Data

The historical data trend for Galapagos NV's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Other Stockholders Equity Chart

Galapagos NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Galapagos NV Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Galapagos NV Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity


Galapagos NV Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Galapagos NV's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Galapagos NV (BSP:G1LP34) Business Description

Address
Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800
Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.

Galapagos NV (BSP:G1LP34) Headlines

No Headlines